nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RIPK2—synovial membrane of synovial joint—osteoarthritis	0.0174	0.211	CbGeAlD
Vandetanib—KDR—hindlimb—osteoarthritis	0.0103	0.125	CbGeAlD
Vandetanib—ORM1—vertebral column—osteoarthritis	0.00977	0.118	CbGeAlD
Vandetanib—STK35—tendon—osteoarthritis	0.00286	0.0346	CbGeAlD
Vandetanib—ABL2—tendon—osteoarthritis	0.00278	0.0337	CbGeAlD
Vandetanib—RIPK2—tendon—osteoarthritis	0.00263	0.0319	CbGeAlD
Vandetanib—VEGFA—tendon—osteoarthritis	0.00263	0.0318	CbGeAlD
Vandetanib—FMO1—tendon—osteoarthritis	0.00261	0.0316	CbGeAlD
Vandetanib—IRAK4—tendon—osteoarthritis	0.00257	0.0311	CbGeAlD
Vandetanib—RET—tendon—osteoarthritis	0.00234	0.0283	CbGeAlD
Vandetanib—FGR—tendon—osteoarthritis	0.00234	0.0283	CbGeAlD
Vandetanib—AXL—tendon—osteoarthritis	0.00233	0.0282	CbGeAlD
Vandetanib—SLK—tendon—osteoarthritis	0.00224	0.0271	CbGeAlD
Vandetanib—FYN—tendon—osteoarthritis	0.00218	0.0264	CbGeAlD
Vandetanib—MAP4K5—tendon—osteoarthritis	0.00213	0.0258	CbGeAlD
Vandetanib—TEK—tendon—osteoarthritis	0.00213	0.0258	CbGeAlD
Vandetanib—EPHB6—tendon—osteoarthritis	0.00204	0.0246	CbGeAlD
Vandetanib—YES1—tendon—osteoarthritis	0.00197	0.0238	CbGeAlD
Vandetanib—STK10—tendon—osteoarthritis	0.00195	0.0236	CbGeAlD
Vandetanib—KDR—tendon—osteoarthritis	0.00174	0.0211	CbGeAlD
Vandetanib—MAP2K5—tendon—osteoarthritis	0.00174	0.0211	CbGeAlD
Vandetanib—PDGFRB—tendon—osteoarthritis	0.00151	0.0182	CbGeAlD
Vandetanib—ABL1—tendon—osteoarthritis	0.00134	0.0163	CbGeAlD
Vandetanib—ABCC1—tendon—osteoarthritis	0.00102	0.0124	CbGeAlD
Vandetanib—RIPK2—Innate Immune System—IL6—osteoarthritis	8.44e-05	9.2e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—CXCL8—osteoarthritis	8.42e-05	9.18e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—IL6—osteoarthritis	8.41e-05	9.17e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL1B—osteoarthritis	8.4e-05	9.15e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—SMAD3—osteoarthritis	8.39e-05	9.14e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TGFB1—osteoarthritis	8.28e-05	9.03e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	8.16e-05	8.9e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—ESR1—osteoarthritis	8.13e-05	8.86e-05	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—IL6—osteoarthritis	8.09e-05	8.82e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—SMAD3—osteoarthritis	8.08e-05	8.81e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL1B—osteoarthritis	8.08e-05	8.81e-05	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—IL6—osteoarthritis	8.06e-05	8.78e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL1B—osteoarthritis	8.05e-05	8.78e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FN1—osteoarthritis	8.03e-05	8.76e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SMAD3—osteoarthritis	7.98e-05	8.7e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CRP—osteoarthritis	7.93e-05	8.65e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1A—osteoarthritis	7.9e-05	8.62e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—PTGS2—osteoarthritis	7.83e-05	8.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—BMP2—osteoarthritis	7.8e-05	8.5e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—LEP—osteoarthritis	7.79e-05	8.49e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CRP—osteoarthritis	7.77e-05	8.47e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CRP—osteoarthritis	7.73e-05	8.43e-05	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—IL6—osteoarthritis	7.73e-05	8.43e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SMAD3—osteoarthritis	7.71e-05	8.41e-05	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—IL6—osteoarthritis	7.69e-05	8.39e-05	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—IL6—osteoarthritis	7.66e-05	8.35e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CRP—osteoarthritis	7.65e-05	8.34e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MMP9—osteoarthritis	7.62e-05	8.3e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1A—osteoarthritis	7.62e-05	8.3e-05	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—IL6—osteoarthritis	7.61e-05	8.3e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—LEP—osteoarthritis	7.59e-05	8.28e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TGFB1—osteoarthritis	7.58e-05	8.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP9—osteoarthritis	7.56e-05	8.24e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—BMP2—osteoarthritis	7.51e-05	8.19e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—LEP—osteoarthritis	7.51e-05	8.19e-05	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—IL6—osteoarthritis	7.44e-05	8.11e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—ESR1—osteoarthritis	7.44e-05	8.11e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SMAD3—osteoarthritis	7.41e-05	8.08e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL1B—osteoarthritis	7.4e-05	8.07e-05	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—IL6—osteoarthritis	7.4e-05	8.06e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—PTGS2—osteoarthritis	7.35e-05	8.01e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FN1—osteoarthritis	7.35e-05	8.01e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MMP1—osteoarthritis	7.34e-05	8e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TGFB1—osteoarthritis	7.32e-05	7.98e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TGFB1—osteoarthritis	7.29e-05	7.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by NGF—IL6—osteoarthritis	7.27e-05	7.92e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—ESR1—osteoarthritis	7.25e-05	7.9e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TGFB1—osteoarthritis	7.21e-05	7.86e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TGFB1—osteoarthritis	7.18e-05	7.83e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—ESR1—osteoarthritis	7.17e-05	7.81e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FN1—osteoarthritis	7.16e-05	7.8e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TGFB1—osteoarthritis	7.15e-05	7.79e-05	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—IL6—osteoarthritis	7.12e-05	7.76e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTO1—osteoarthritis	7.09e-05	7.73e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FN1—osteoarthritis	7.08e-05	7.72e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TGFB1—osteoarthritis	7.07e-05	7.71e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IGF1—osteoarthritis	7.04e-05	7.67e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—IL6—osteoarthritis	7e-05	7.63e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—SMAD3—osteoarthritis	6.98e-05	7.61e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—BGN—osteoarthritis	6.86e-05	7.48e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TNF—osteoarthritis	6.84e-05	7.45e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoarthritis	6.83e-05	7.44e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—IL6—osteoarthritis	6.82e-05	7.44e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—LEP—osteoarthritis	6.82e-05	7.44e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TNF—osteoarthritis	6.8e-05	7.42e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—IL6—osteoarthritis	6.76e-05	7.36e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1A—osteoarthritis	6.74e-05	7.35e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SMAD3—osteoarthritis	6.73e-05	7.34e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—osteoarthritis	6.73e-05	7.34e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—FN1—osteoarthritis	6.7e-05	7.3e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FMOD—osteoarthritis	6.66e-05	7.26e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BMP2—osteoarthritis	6.65e-05	7.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CRP—osteoarthritis	6.61e-05	7.2e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—LEP—osteoarthritis	6.59e-05	7.18e-05	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—IL6—osteoarthritis	6.58e-05	7.17e-05	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—IL6—osteoarthritis	6.53e-05	7.12e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ESR1—osteoarthritis	6.51e-05	7.1e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1B—osteoarthritis	6.5e-05	7.08e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP3—osteoarthritis	6.49e-05	7.07e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP9—osteoarthritis	6.45e-05	7.03e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IGF1—osteoarthritis	6.44e-05	7.02e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FN1—osteoarthritis	6.43e-05	7.01e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CRP—osteoarthritis	6.37e-05	6.94e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP3—osteoarthritis	6.35e-05	6.93e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ESR1—osteoarthritis	6.29e-05	6.86e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TGFB1—osteoarthritis	6.28e-05	6.84e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IGF1—osteoarthritis	6.27e-05	6.84e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP3—osteoarthritis	6.25e-05	6.82e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—IL6—osteoarthritis	6.24e-05	6.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TGFB1—osteoarthritis	6.23e-05	6.79e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FN1—osteoarthritis	6.22e-05	6.78e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IGF1—osteoarthritis	6.2e-05	6.76e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—IL6—osteoarthritis	6.2e-05	6.76e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—SMAD3—osteoarthritis	5.96e-05	6.49e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TGFB1—osteoarthritis	5.89e-05	6.42e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SMAD3—osteoarthritis	5.87e-05	6.4e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IGF1—osteoarthritis	5.87e-05	6.4e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—osteoarthritis	5.81e-05	6.34e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SMAD3—osteoarthritis	5.75e-05	6.27e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL6—osteoarthritis	5.71e-05	6.22e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SMAD3—osteoarthritis	5.66e-05	6.17e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CXCL8—osteoarthritis	5.66e-05	6.17e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IGF1—osteoarthritis	5.64e-05	6.15e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CRP—osteoarthritis	5.64e-05	6.14e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—IL6—osteoarthritis	5.61e-05	6.11e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—IL6—osteoarthritis	5.52e-05	6.01e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—IL6—osteoarthritis	5.49e-05	5.99e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IGF1—osteoarthritis	5.45e-05	5.94e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL6—osteoarthritis	5.44e-05	5.93e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—IL6—osteoarthritis	5.43e-05	5.92e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGES—osteoarthritis	5.43e-05	5.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP3—osteoarthritis	5.4e-05	5.89e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TGFB1—osteoarthritis	5.31e-05	5.79e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—TGFB1—osteoarthritis	5.31e-05	5.79e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TGFB1—osteoarthritis	5.21e-05	5.68e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP3—osteoarthritis	5.21e-05	5.68e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CXCL8—osteoarthritis	5.18e-05	5.64e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MMP9—osteoarthritis	5.12e-05	5.58e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CXCL8—osteoarthritis	5.04e-05	5.5e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—LEP—osteoarthritis	5.02e-05	5.47e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CXCL8—osteoarthritis	4.99e-05	5.44e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IL6—osteoarthritis	4.98e-05	5.42e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—osteoarthritis	4.96e-05	5.41e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1B—osteoarthritis	4.95e-05	5.4e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL6—osteoarthritis	4.92e-05	5.36e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—LEP—osteoarthritis	4.91e-05	5.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTGS2—osteoarthritis	4.91e-05	5.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SMAD3—osteoarthritis	4.89e-05	5.33e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IL6—osteoarthritis	4.87e-05	5.31e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IL6—osteoarthritis	4.85e-05	5.29e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1B—osteoarthritis	4.85e-05	5.28e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—LEP—osteoarthritis	4.84e-05	5.27e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1B—osteoarthritis	4.82e-05	5.26e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—osteoarthritis	4.8e-05	5.23e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ESR1—osteoarthritis	4.79e-05	5.22e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1B—osteoarthritis	4.77e-05	5.2e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—osteoarthritis	4.73e-05	5.16e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FN1—osteoarthritis	4.73e-05	5.16e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—osteoarthritis	4.73e-05	5.16e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—osteoarthritis	4.73e-05	5.16e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—osteoarthritis	4.71e-05	5.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SMAD3—osteoarthritis	4.71e-05	5.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CXCL8—osteoarthritis	4.7e-05	5.13e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ESR1—osteoarthritis	4.69e-05	5.11e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—osteoarthritis	4.69e-05	5.11e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MMP9—osteoarthritis	4.68e-05	5.1e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FN1—osteoarthritis	4.63e-05	5.05e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ESR1—osteoarthritis	4.62e-05	5.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP3—osteoarthritis	4.61e-05	5.03e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MMP9—osteoarthritis	4.56e-05	4.97e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FN1—osteoarthritis	4.56e-05	4.97e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CXCL8—osteoarthritis	4.53e-05	4.94e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MMP9—osteoarthritis	4.51e-05	4.92e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—osteoarthritis	4.43e-05	4.83e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CXCL8—osteoarthritis	4.38e-05	4.77e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—osteoarthritis	4.34e-05	4.73e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—osteoarthritis	4.34e-05	4.73e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TGFB1—osteoarthritis	4.22e-05	4.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—LEP—osteoarthritis	4.18e-05	4.56e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SMAD3—osteoarthritis	4.17e-05	4.55e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF1—osteoarthritis	4.15e-05	4.52e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—osteoarthritis	4.14e-05	4.52e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1B—osteoarthritis	4.12e-05	4.49e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP9—osteoarthritis	4.1e-05	4.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—osteoarthritis	4.09e-05	4.46e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF1—osteoarthritis	4.06e-05	4.43e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—LEP—osteoarthritis	4.03e-05	4.39e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—osteoarthritis	4e-05	4.36e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—osteoarthritis	4e-05	4.36e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF1—osteoarthritis	4e-05	4.36e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—osteoarthritis	3.99e-05	4.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ESR1—osteoarthritis	3.99e-05	4.35e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1B—osteoarthritis	3.97e-05	4.33e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP9—osteoarthritis	3.96e-05	4.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FN1—osteoarthritis	3.94e-05	4.3e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—osteoarthritis	3.94e-05	4.3e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TGFB1—osteoarthritis	3.86e-05	4.21e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ESR1—osteoarthritis	3.85e-05	4.19e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTO1—osteoarthritis	3.83e-05	4.17e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—osteoarthritis	3.81e-05	4.15e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FN1—osteoarthritis	3.8e-05	4.14e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TGFB1—osteoarthritis	3.76e-05	4.1e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TGFB1—osteoarthritis	3.72e-05	4.05e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BGN—osteoarthritis	3.71e-05	4.04e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—osteoarthritis	3.63e-05	3.96e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LEP—osteoarthritis	3.57e-05	3.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TGFB1—osteoarthritis	3.55e-05	3.87e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—osteoarthritis	3.54e-05	3.85e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—osteoarthritis	3.52e-05	3.84e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—osteoarthritis	3.52e-05	3.83e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—osteoarthritis	3.49e-05	3.8e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—osteoarthritis	3.45e-05	3.77e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—osteoarthritis	3.42e-05	3.73e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ESR1—osteoarthritis	3.4e-05	3.71e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—osteoarthritis	3.38e-05	3.68e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FN1—osteoarthritis	3.36e-05	3.67e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL8—osteoarthritis	3.34e-05	3.64e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—osteoarthritis	3.33e-05	3.63e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—osteoarthritis	3.27e-05	3.56e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—osteoarthritis	3.27e-05	3.56e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—osteoarthritis	3.22e-05	3.51e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—osteoarthritis	3.2e-05	3.49e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—osteoarthritis	3.18e-05	3.47e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—osteoarthritis	3.14e-05	3.42e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—osteoarthritis	3.02e-05	3.29e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—osteoarthritis	2.96e-05	3.22e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—osteoarthritis	2.95e-05	3.22e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—osteoarthritis	2.95e-05	3.21e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—osteoarthritis	2.91e-05	3.17e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—osteoarthritis	2.91e-05	3.17e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—osteoarthritis	2.9e-05	3.16e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—osteoarthritis	2.85e-05	3.11e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—osteoarthritis	2.84e-05	3.09e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—osteoarthritis	2.83e-05	3.09e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—osteoarthritis	2.82e-05	3.08e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—osteoarthritis	2.8e-05	3.06e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—osteoarthritis	2.79e-05	3.05e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—osteoarthritis	2.78e-05	3.03e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—osteoarthritis	2.68e-05	2.92e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—osteoarthritis	2.68e-05	2.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—osteoarthritis	2.64e-05	2.88e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—osteoarthritis	2.58e-05	2.81e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—osteoarthritis	2.55e-05	2.78e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—osteoarthritis	2.52e-05	2.75e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—osteoarthritis	2.51e-05	2.74e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—osteoarthritis	2.49e-05	2.71e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—osteoarthritis	2.46e-05	2.68e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—osteoarthritis	2.43e-05	2.65e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—osteoarthritis	2.42e-05	2.64e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—osteoarthritis	2.41e-05	2.63e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—osteoarthritis	2.4e-05	2.61e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—osteoarthritis	2.37e-05	2.58e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—osteoarthritis	2.36e-05	2.58e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—osteoarthritis	2.33e-05	2.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—osteoarthritis	2.23e-05	2.43e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—osteoarthritis	2.15e-05	2.34e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—osteoarthritis	2.14e-05	2.34e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—osteoarthritis	2.07e-05	2.26e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—osteoarthritis	2.06e-05	2.24e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—osteoarthritis	2e-05	2.18e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—osteoarthritis	1.97e-05	2.15e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—osteoarthritis	1.9e-05	2.07e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—osteoarthritis	1.87e-05	2.04e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—osteoarthritis	1.83e-05	2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—osteoarthritis	1.81e-05	1.97e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—osteoarthritis	1.77e-05	1.93e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—osteoarthritis	1.56e-05	1.7e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—osteoarthritis	1.5e-05	1.64e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—osteoarthritis	1.33e-05	1.45e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—osteoarthritis	1.07e-05	1.16e-05	CbGpPWpGaD
